Clinical application of adagrasib

Adagrasib (Adagrasib) is a new targeted therapy primarily indicated for the treatment of locally advanced or metastatic KRAS G12C mutated non-small cell lung cancer in patients who have received at least one previous systemic therapy. Adagrasiib is a covalent inhibitor of KRAS G12C that irreversibly and selectively binds to and blocks the inactive phosphate compound of KRAS G12C. Therefore, adagrasib, which has minimal off-target activity, inhibits the growth and survival of mutant cancer KRAS G12C tumor cells.

The mechanism of action of adagrasib is based on the important role of KRAS protein in cell signaling. In normal cells, KRAS is activated by binding to avian triphosphate (GTP), thereby promoting the activation of the MAP kinase pathway and the transmission of intracellular signals. KRAS is deactivated when GTP is hydrolyzed to diphosphate (GDP), a mechanism that acts as an on/off system that regulates cell growth. However, in the case of the KRAS G12C mutation, replacement of cysteine u200bu200bwith Gly12 impairs GTP hydrolysis, allowing KRAS to maintain its active form, leading to uncontrolled cell proliferation and growth and malignant transformation.

Since the original drug of adagrasib has not yet been launched in China, patients can only purchase adagrasib through overseas channels. The specifications of the original version of adagrasib in the United States The price of each box of 200mg*180 tablets is more than 100,000 yuan (the price may fluctuate due to the exchange rate), which is very expensive. Currently, there are no generic adagrasibu produced in other countries overseas. For more drug information and specific prices, please consult Yaode Medical Consultant.